FDA Sought To Suppress Vioxx Safety Data, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Based upon Finance Committee investigators’ interview with FDA Office of Drug Safety’s David Graham, Grassley maintains the agency delayed presentation of a study that found an increased cardiovascular risk associated with Vioxx.
You may also be interested in...
Senate Vioxx Hearing To Include Merck’s Gilmartin, FDA’s Crawford
A Nov. 18 Senate Finance Committee hearing on the withdrawal of Vioxx will include testimony from Merck CEO Ray Gilmartin
Senate Vioxx Hearing To Include Merck’s Gilmartin, FDA’s Crawford
A Nov. 18 Senate Finance Committee hearing on the withdrawal of Vioxx will include testimony from Merck CEO Ray Gilmartin
Merck Vioxx Communications With FDA Questioned By Senate Finance Cmte.
Sen. Grassley (R-Iowa) asks Merck to provide copies of its communications with FDA relating to Vioxx. The Finance chair is concerned about a possible “agreement” that may have allowed Vioxx to remain on the market longer than it would have otherwise.